Gilberto Lopes | touchONCOLOGY

A Comprehensive Catalogue of Stromal Cells in Human Lung Tumours at Single-Cell Resolution

FDA Grants Accelerated Approval to Ipilimumab in Combination with Nivolumab for MSI-H or dMMR mCRC

EMA Recommends Granting a Marketing Authorisation for Liposomal Formulation of a Fixed Combination of Daunorubicin and Cytarabine

FDA Approves the Ventana PD-L1 (SP142) Assay for PD L1 Expression in ≥ 5% IC in Urothelial Carcinoma Tissue

Study Identifies Factors Associated with Diffuse Intrinsic Pontine Glioma that Indicate Better Survival

EMA Recommends Granting Marketing Authorisations for the First Two CAR T-cell Therapies in the EU

Sylvester Comprehensive Cancer Center, University of Miami, FL, US

Authored articles:

Can we Continue to Afford Access to Cancer Treatment?

Nils Wilking, Gilberto Lopes, Klaus Meier, Steven Simoens, Wim van Harten, Arnold Vulto

European Oncology & Haematology

European Oncology & Haematology, 2017;13(2):114–9 DOI: https://doi.org/10.17925/EOH.2017.13.02.114

What Happens when the Cost of Cancer Care Becomes Unsustainable?

Steven Simoens, Wim van Harten, Gilberto Lopes, Arnold Vulto, Klaus Meier, Nils Wilking

European Oncology & Haematology

European Oncology & Haematology, 2017;13(2):108–13 DOI: https://doi.org/10.17925/EOH.2017.13.02.108

Potential Solutions for Sustaining the Costs of Cancer Drugs

Gilberto Lopes, Arnold Vulto, Nils Wilking, Wim van Harten, Klaus Meier, Steven Simoens

European Oncology & Haematology

European Oncology & Haematology, 2017;13(2):102–7 DOI: https://doi.org/10.17925/EOH.2017.13.02.102